Plasmid Market, By General Type Plasmid (Conjugative, Non-Conjugative); By Specific Plasmid Types (F-Plasmids, Resistance Plasmids, Virulence Plasmids, Degradative Plasmids, Col Plasmids, Cryptic Plasmids); By Application (Transfection, Gene Therapy, Recombinant DNA Technology, Others); By Region (U.S., Canada, Mexico, France, The UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America, ) — Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019–2027
Industry Trends
A plasmid is a small, circular, extrachromosomal, double-stranded deoxyribonucleic acid (DNA) molecule which is distinct from a cell's chromosomal DNA. Plasmids are important vehicles for the communication of genetic information between bacteria. Plasmid is a genetic structure in a cell that can replicate independently of chromosomal DNA, and usually carry genes. The 21st century has witnessed a greater understanding and evolution of humans and diseases. This has brought about an increased potential and awareness of genomics of microbial plasmids, thereby supporting the plasmid market growth. According to an article published in the National Center for Biotechnology Information (NCBI), over the past six decades, a huge number of plasmids have been identified and isolated from various microbes. Due to revolution of sequencing technology, over 4,600 complete sequences of plasmids found in bacteria, eukaryotes, and archaea have been determined. The classification of plasmids has been helping to understand their host ranges, features, and microbial evolution as well as to efficiently use them as genetic tools for microbial engineering.
Worldwide rising prevalence of cancer, genetic diseases, and infectious diseases coupled with growing awareness about gene therapy is majorly driving growth of the global plasmid market. For instance, as per the data published by World Health Organization (WHO), the worldwide prevalence of all single gene (monogenic) diseases at birth is approximately 10 in 1,000 individuals currently. Plasmids find significance in the fields of gene therapy, oncology, and vaccines, among others. In addition, the presence of favorable government initiatives & grants and a growth in investment by private companies on R&D of plasmid deoxyribonucleic acid (DNA) are likely to catapult the market growth during the forecast period.
The global plasmid market was valued at US$ 89.52 million in 2018 and is estimated to reach US$ 447.68 million by 2027, growing at a CAGR of 19.5% over the forecast period from 2019 to 2027.
Global Plasmid Market Size (US$ Million), 2019–2027
General Type Plasmid Outlook:
On the basis of general type plasmid, the global plasmid market has been classified into conjugative and non-conjugative. The conjugative segment spearheaded the market in 2018 owing to their ability to horizontally transmit genes by conjugation, which provides autonomy from host replication and offers a high number of alternative hosts within heterogeneous individuals.
Specific Plasmid Types Outlook:
Based on the specific plasmid types, the global plasmid market has been categorized into F-plasmids, resistance plasmids, virulence plasmids, degradative plasmids, Col plasmids, and cryptic plasmids. Fertility plasmids or F-plasmids contain transfer genes that allow genes to transfer from one bacteria to another through conjugation. These make up the broad category of conjugative plasmids. F-plasmids are episomes, which are plasmids that can be inserted into chromosomal DNA. The F-plasmids segment held the highest chunk of the plasmid market in 2018 and is expected to continue its dominance throughout the forecast period as F plasmids facilitate the genetic exchange of material between cells and control sexual functions of bacteria with a fertility inhibition (FIN) systems. On the other hand, the resistance plasmids segment is expected to register a comparatively higher CAGR over the review period as the resistance or R-plasmids code for products that provide resistance to antibiotics or other bacterial growth inhibitors.
Application Outlook:
The global plasmid market by application has been bifurcated into transfection, gene therapy, recombinant DNA technology, and others. Increasing funding in R&D pertaining to gene therapy, favorable government support and growing awareness about gene therapy are the major factors supported the dominance of the gene therapy segment in 2018. Additionally, the recombinant DNA technology makes use of plasmids for the drug delivery to insert the desired drug into the body. They are also involved in causing antibiotic resistance and are used to kill harmful bacteria from the body. Thus, this significant use of plasmids in recombinant DNA technology is expected to assist in the lucrative growth of the recombinant DNA technology segment over the study period.
Regional Outlook:
North America commanded the global plasmid market in 2018 attributed to the presence of prominent market players & biopharmaceutical manufacturers, growing awareness regarding gene therapy, and increasing investments in gene therapy products in the U.S. and Canada. On the other hand, surging number of susceptible population to various chronic diseases and wide availability of novel products providing improved healthcare to the patients at marginally lower costs in China and India are expected to contribute to the significant market growth of the Asia Pacific region.
Competitive Landscape
The report provides both, qualitative and quantitative research of the global plasmid market. It is a definite source which provides penetrative insights into the rational scenario and favored manufacturing or production methods adopted by key market players based on the past and current scenario of the market. The report also provides extensive research on the key players in the market in addition to a comprehensive overview on their competitiveness. Key business strategies such as mergers and acquisitions (M&As), new product launches, collaborations, and partnerships adopted by the major players are also meticulously highlighted. For each company, the report recognizes their headquarters, competitors, product/service type, application and specification, pricing, and gross margin.
The primary market participants in the global plasmid market are Aldevron, GenScript, PlasmidFactory GmbH & Co. KG, VGXI, Inc., Oxford Genetics Ltd., Applied StemCell, Altogen Biosystems, Cobra Biologics, Copernicus Therapeutics, Inc., Takara Bio Inc., InvivoGen, Miltenyi Biotec, MaxCyte, Inc., Mirus Bio LLC, MolMed S.p.A., GenePharma Co., Ltd., Polyplus Transfection, and other market participants.
Global Plasmid Market:
- By General Type Plasmid
- Conjugative
- Non-Conjugative
- By Specific Plasmid Types
- F-Plasmids
- Resistance Plasmids
- Virulence Plasmids
- Degradative Plasmids
- Col Plasmids
- Cryptic Plasmids
- By Application
- Transfection
- Gene Therapy
- Recombinant DNA Technology
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxemburg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East and Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Plasmid Market
6. Market Synopsis:
Plasmid Market
7. Plasmid Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Plasmid Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Plasmid Market
7.6. Porter’s
Five Force Analysis
8. Global Plasmid Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Plasmid Market Revenue (US$ Mn)
8.2. Global
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
8.2.1. Conjugative
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Non-Conjugative
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By
General Type Plasmid
9. Global Plasmid Market Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
9.2.1. F-Plasmids
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Resistance
Plasmids
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. Virulence
Plasmids
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.2.4. Degradative
Plasmids
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2013 – 2018
9.2.4.3. Market
Forecast, 2019 – 2027
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2013 – 2018
9.2.4.5.1.2. Market
Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2018
9.2.4.5.2.2. Market
Forecast, 2019 – 2027
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2018
9.2.4.5.3.2. Market
Forecast, 2019 – 2027
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2018
9.2.4.5.4.2. Market
Forecast, 2019 – 2027
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2013 – 2018
9.2.4.5.5.2. Market
Forecast, 2019 – 2027
9.2.5. Col
Plasmids
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2013 – 2018
9.2.5.3. Market
Forecast, 2019 – 2027
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2013 – 2018
9.2.5.5.1.2. Market
Forecast, 2019 – 2027
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2013 – 2018
9.2.5.5.2.2. Market
Forecast, 2019 – 2027
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2013 – 2018
9.2.5.5.3.2. Market
Forecast, 2019 – 2027
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2013 – 2018
9.2.5.5.4.2. Market
Forecast, 2019 – 2027
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2013 – 2018
9.2.5.5.5.2. Market
Forecast, 2019 – 2027
9.2.6. Cryptic
Plasmids
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2013 – 2018
9.2.6.3. Market
Forecast, 2019 – 2027
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2013 – 2018
9.2.6.5.1.2. Market
Forecast, 2019 – 2027
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2013 – 2018
9.2.6.5.2.2. Market
Forecast, 2019 – 2027
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2013 – 2018
9.2.6.5.3.2. Market
Forecast, 2019 – 2027
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2013 – 2018
9.2.6.5.4.2. Market
Forecast, 2019 – 2027
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2013 – 2018
9.2.6.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Specific Plasmid Types
10. Global Plasmid Market Analysis and Forecasts, 2019 – 2027
10.1. Overview
10.2. Global
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
10.2.1. Transfection
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Gene
Therapy
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. Recombinant
DNA Technology
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2013 – 2018
10.2.3.3. Market
Forecast, 2019 – 2027
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2013 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2013 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2013 – 2018
10.2.4.3. Market
Forecast, 2019 – 2027
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2013 – 2018
10.2.4.5.1.2. Market
Forecast, 2019 – 2027
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2013 – 2018
10.2.4.5.2.2. Market
Forecast, 2019 – 2027
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2013 – 2018
10.2.4.5.3.2. Market
Forecast, 2019 – 2027
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2013 – 2018
10.2.4.5.4.2. Market
Forecast, 2019 – 2027
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2013 – 2018
10.2.4.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By
Application
11. North America Plasmid Market Analysis and Forecasts, 2019 -
2027
11.1. Overview
11.1.1. North
America Plasmid Market Revenue (US$ Mn)
11.2. North
America Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
11.2.1. Conjugative
11.2.2. Non-Conjugative
11.3. North
America Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid
Types
11.3.1. F-Plasmids
11.3.2. Resistance
Plasmids
11.3.3. Virulence
Plasmids
11.3.4. Degradative
Plasmids
11.3.5. Col
Plasmids
11.3.6. Cryptic
Plasmids
11.4. North
America Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
11.4.1. Transfection
11.4.2. Gene
Therapy
11.4.3. Recombinant
DNA Technology
11.4.4. Others
11.5. North
America Plasmid Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
11.5.1.1.1. Conjugative
11.5.1.1.2. Non-Conjugative
11.5.1.2. U.S
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
11.5.1.2.1. F-Plasmids
11.5.1.2.2. Resistance
Plasmids
11.5.1.2.3. Virulence
Plasmids
11.5.1.2.4. Degradative
Plasmids
11.5.1.2.5. Col
Plasmids
11.5.1.2.6. Cryptic
Plasmids
11.5.1.3. U.S
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
11.5.1.3.1. Transfection
11.5.1.3.2. Gene
Therapy
11.5.1.3.3. Recombinant
DNA Technology
11.5.1.3.4. Others
11.5.2. Canada
11.5.2.1. Canada
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
11.5.2.1.1. Conjugative
11.5.2.1.2. Non-Conjugative
11.5.2.2. Canada
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
11.5.2.2.1. F-Plasmids
11.5.2.2.2. Resistance
Plasmids
11.5.2.2.3. Virulence
Plasmids
11.5.2.2.4. Degradative
Plasmids
11.5.2.2.5. Col
Plasmids
11.5.2.2.6. Cryptic
Plasmids
11.5.2.3. Canada
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.3.1. Transfection
11.5.2.3.2. Gene
Therapy
11.5.2.3.3. Recombinant
DNA Technology
11.5.2.3.4. Others
11.5.3. Mexico
11.5.3.1. Mexico
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
11.5.3.1.1. Conjugative
11.5.3.1.2. Non-Conjugative
11.5.3.2. Mexico
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
11.5.3.2.1. F-Plasmids
11.5.3.2.2. Resistance
Plasmids
11.5.3.2.3. Virulence
Plasmids
11.5.3.2.4. Degradative
Plasmids
11.5.3.2.5. Col
Plasmids
11.5.3.2.6. Cryptic
Plasmids
11.5.3.3. Mexico
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
11.5.3.3.1. Transfection
11.5.3.3.2. Gene
Therapy
11.5.3.3.3. Recombinant
DNA Technology
11.5.3.3.4. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type
Plasmid
11.5.4.1.1. Conjugative
11.5.4.1.2. Non-Conjugative
11.5.4.2. Rest
of North America Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific
Plasmid Types
11.5.4.2.1. F-Plasmids
11.5.4.2.2. Resistance
Plasmids
11.5.4.2.3. Virulence
Plasmids
11.5.4.2.4. Degradative
Plasmids
11.5.4.2.5. Col
Plasmids
11.5.4.2.6. Cryptic
Plasmids
11.5.4.3. Rest
of North America Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
11.5.4.3.1. Transfection
11.5.4.3.2. Gene
Therapy
11.5.4.3.3. Recombinant
DNA Technology
11.5.4.3.4. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
General Type Plasmid
11.6.3. By
Specific Plasmid Types
11.6.4. By
Application
12. Europe Plasmid Market Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Europe
Plasmid Market Revenue (US$ Mn)
12.2. Europe
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
12.2.1. Conjugative
12.2.2. Non-Conjugative
12.3. Europe
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
12.3.1. F-Plasmids
12.3.2. Resistance
Plasmids
12.3.3. Virulence
Plasmids
12.3.4. Degradative
Plasmids
12.3.5. Col
Plasmids
12.3.6. Cryptic
Plasmids
12.4. Europe
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
12.4.1. Transfection
12.4.2. Gene
Therapy
12.4.3. Recombinant
DNA Technology
12.4.4. Others
12.5. Europe
Plasmid Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
12.5.1.1.1. Conjugative
12.5.1.1.2. Non-Conjugative
12.5.1.2. France
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
12.5.1.2.1. F-Plasmids
12.5.1.2.2. Resistance
Plasmids
12.5.1.2.3. Virulence
Plasmids
12.5.1.2.4. Degradative
Plasmids
12.5.1.2.5. Col
Plasmids
12.5.1.2.6. Cryptic
Plasmids
12.5.1.3. France
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.3.1. Transfection
12.5.1.3.2. Gene
Therapy
12.5.1.3.3. Recombinant
DNA Technology
12.5.1.3.4. Others
12.5.2. The UK
12.5.2.1. The
UK Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
12.5.2.1.1. Conjugative
12.5.2.1.2. Non-Conjugative
12.5.2.2. The
UK Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
12.5.2.2.1. F-Plasmids
12.5.2.2.2. Resistance
Plasmids
12.5.2.2.3. Virulence
Plasmids
12.5.2.2.4. Degradative
Plasmids
12.5.2.2.5. Col
Plasmids
12.5.2.2.6. Cryptic
Plasmids
12.5.2.3. The
UK Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
12.5.2.3.1. Transfection
12.5.2.3.2. Gene
Therapy
12.5.2.3.3. Recombinant
DNA Technology
12.5.2.3.4. Others
12.5.3. Spain
12.5.3.1. Spain
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
12.5.3.1.1. Conjugative
12.5.3.1.2. Non-Conjugative
12.5.3.2. Spain
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
12.5.3.2.1. F-Plasmids
12.5.3.2.2. Resistance
Plasmids
12.5.3.2.3. Virulence
Plasmids
12.5.3.2.4. Degradative
Plasmids
12.5.3.2.5. Col
Plasmids
12.5.3.2.6. Cryptic
Plasmids
12.5.3.3. Spain
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.3.1. Transfection
12.5.3.3.2. Gene
Therapy
12.5.3.3.3. Recombinant
DNA Technology
12.5.3.3.4. Others
12.5.4. Germany
12.5.4.1. Germany
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
12.5.4.1.1. Conjugative
12.5.4.1.2. Non-Conjugative
12.5.4.2. Germany
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
12.5.4.2.1. F-Plasmids
12.5.4.2.2. Resistance
Plasmids
12.5.4.2.3. Virulence
Plasmids
12.5.4.2.4. Degradative
Plasmids
12.5.4.2.5. Col
Plasmids
12.5.4.2.6. Cryptic
Plasmids
12.5.4.3. Germany
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.3.1. Transfection
12.5.4.3.2. Gene
Therapy
12.5.4.3.3. Recombinant
DNA Technology
12.5.4.3.4. Others
12.5.5. Italy
12.5.5.1. Italy
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
12.5.5.1.1. Conjugative
12.5.5.1.2. Non-Conjugative
12.5.5.2. Italy
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
12.5.5.2.1. F-Plasmids
12.5.5.2.2. Resistance
Plasmids
12.5.5.2.3. Virulence
Plasmids
12.5.5.2.4. Degradative
Plasmids
12.5.5.2.5. Col
Plasmids
12.5.5.2.6. Cryptic
Plasmids
12.5.5.3. Italy
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
12.5.5.3.1. Transfection
12.5.5.3.2. Gene
Therapy
12.5.5.3.3. Recombinant
DNA Technology
12.5.5.3.4. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type
Plasmid
12.5.6.1.1. Conjugative
12.5.6.1.2. Non-Conjugative
12.5.6.2. Nordic
Countries Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid
Types
12.5.6.2.1. F-Plasmids
12.5.6.2.2. Resistance
Plasmids
12.5.6.2.3. Virulence
Plasmids
12.5.6.2.4. Degradative
Plasmids
12.5.6.2.5. Col
Plasmids
12.5.6.2.6. Cryptic
Plasmids
12.5.6.3. Nordic
Countries Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
12.5.6.3.1. Transfection
12.5.6.3.2. Gene
Therapy
12.5.6.3.3. Recombinant
DNA Technology
12.5.6.3.4. Others
12.5.6.4. Nordic
Countries Plasmid Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
12.5.7.1.1. Conjugative
12.5.7.1.2. Non-Conjugative
12.5.7.2. Benelux
Union Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
12.5.7.2.1. F-Plasmids
12.5.7.2.2. Resistance
Plasmids
12.5.7.2.3. Virulence
Plasmids
12.5.7.2.4. Degradative
Plasmids
12.5.7.2.5. Col
Plasmids
12.5.7.2.6. Cryptic
Plasmids
12.5.7.3. Benelux
Union Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
12.5.7.3.1. Transfection
12.5.7.3.2. Gene
Therapy
12.5.7.3.3. Recombinant
DNA Technology
12.5.7.3.4. Others
12.5.7.4. Benelux
Union Plasmid Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type
Plasmid
12.5.8.1.1. Conjugative
12.5.8.1.2. Non-Conjugative
12.5.8.2. Rest
of Europe Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid
Types
12.5.8.2.1. F-Plasmids
12.5.8.2.2. Resistance
Plasmids
12.5.8.2.3. Virulence
Plasmids
12.5.8.2.4. Degradative
Plasmids
12.5.8.2.5. Col
Plasmids
12.5.8.2.6. Cryptic
Plasmids
12.5.8.3. Rest
of Europe Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
12.5.8.3.1. Transfection
12.5.8.3.2. Gene
Therapy
12.5.8.3.3. Recombinant
DNA Technology
12.5.8.3.4. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
General Type Plasmid
12.6.3. By
Specific Plasmid Types
12.6.4. By
Application
13. Asia Pacific Plasmid Market Analysis and Forecasts, 2019 -
2027
13.1. Overview
13.1.1. Asia
Pacific Plasmid Market Revenue (US$ Mn)
13.2. Asia
Pacific Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
13.2.1. Conjugative
13.2.2. Non-Conjugative
13.3. Asia
Pacific Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid
Types
13.3.1. F-Plasmids
13.3.2. Resistance
Plasmids
13.3.3. Virulence
Plasmids
13.3.4. Degradative
Plasmids
13.3.5. Col
Plasmids
13.3.6. Cryptic
Plasmids
13.4. Asia
Pacific Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
13.4.1. Transfection
13.4.2. Gene Therapy
13.4.3. Recombinant
DNA Technology
13.4.4. Others
13.5. Asia
Pacific Plasmid Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
13.5.1.1.1. Conjugative
13.5.1.1.2. Non-Conjugative
13.5.1.2. China
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
13.5.1.2.1. F-Plasmids
13.5.1.2.2. Resistance
Plasmids
13.5.1.2.3. Virulence
Plasmids
13.5.1.2.4. Degradative
Plasmids
13.5.1.2.5. Col
Plasmids
13.5.1.2.6. Cryptic
Plasmids
13.5.1.3. China
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1.3.1. Transfection
13.5.1.3.2. Gene
Therapy
13.5.1.3.3. Recombinant
DNA Technology
13.5.1.3.4. Others
13.5.2. Japan
13.5.2.1. Japan
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
13.5.2.1.1. Conjugative
13.5.2.1.2. Non-Conjugative
13.5.2.2. Japan
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
13.5.2.2.1. F-Plasmids
13.5.2.2.2. Resistance
Plasmids
13.5.2.2.3. Virulence
Plasmids
13.5.2.2.4. Degradative
Plasmids
13.5.2.2.5. Col
Plasmids
13.5.2.2.6. Cryptic
Plasmids
13.5.2.3. Japan
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
13.5.2.3.1. Transfection
13.5.2.3.2. Gene
Therapy
13.5.2.3.3. Recombinant
DNA Technology
13.5.2.3.4. Others
13.5.3. India
13.5.3.1. India
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
13.5.3.1.1. Conjugative
13.5.3.1.2. Non-Conjugative
13.5.3.2. India
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
13.5.3.2.1. F-Plasmids
13.5.3.2.2. Resistance
Plasmids
13.5.3.2.3. Virulence
Plasmids
13.5.3.2.4. Degradative
Plasmids
13.5.3.2.5. Col
Plasmids
13.5.3.2.6. Cryptic
Plasmids
13.5.3.3. India
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.3.1. Transfection
13.5.3.3.2. Gene
Therapy
13.5.3.3.3. Recombinant
DNA Technology
13.5.3.3.4. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
13.5.4.1.1. Conjugative
13.5.4.1.2. Non-Conjugative
13.5.4.2. New
Zealand Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid
Types
13.5.4.2.1. F-Plasmids
13.5.4.2.2. Resistance
Plasmids
13.5.4.2.3. Virulence
Plasmids
13.5.4.2.4. Degradative
Plasmids
13.5.4.2.5. Col
Plasmids
13.5.4.2.6. Cryptic
Plasmids
13.5.4.3. New
Zealand Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
13.5.4.3.1. Transfection
13.5.4.3.2. Gene
Therapy
13.5.4.3.3. Recombinant
DNA Technology
13.5.4.3.4. Others
13.5.5. Australia
13.5.5.1. Australia
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
13.5.5.1.1. Conjugative
13.5.5.1.2. Non-Conjugative
13.5.5.2. Australia
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
13.5.5.2.1. F-Plasmids
13.5.5.2.2. Resistance
Plasmids
13.5.5.2.3. Virulence
Plasmids
13.5.5.2.4. Degradative
Plasmids
13.5.5.2.5. Col
Plasmids
13.5.5.2.6. Cryptic
Plasmids
13.5.5.3. Australia
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.3.1. Transfection
13.5.5.3.2. Gene
Therapy
13.5.5.3.3. Recombinant
DNA Technology
13.5.5.3.4. Others
13.5.6. South
Korea
13.5.6.1. South
Korea Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
13.5.6.1.1. Conjugative
13.5.6.1.2. Non-Conjugative
13.5.6.2. South
Korea Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
13.5.6.2.1. F-Plasmids
13.5.6.2.2. Resistance
Plasmids
13.5.6.2.3. Virulence
Plasmids
13.5.6.2.4. Degradative
Plasmids
13.5.6.2.5. Col
Plasmids
13.5.6.2.6. Cryptic
Plasmids
13.5.6.3. South
Korea Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
13.5.6.3.1. Transfection
13.5.6.3.2. Gene
Therapy
13.5.6.3.3. Recombinant
DNA Technology
13.5.6.3.4. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
13.5.7.1.1. Conjugative
13.5.7.1.2. Non-Conjugative
13.5.7.2. Southeast
Asia Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
13.5.7.2.1. F-Plasmids
13.5.7.2.2. Resistance
Plasmids
13.5.7.2.3. Virulence
Plasmids
13.5.7.2.4. Degradative
Plasmids
13.5.7.2.5. Col
Plasmids
13.5.7.2.6. Cryptic
Plasmids
13.5.7.3. Southeast
Asia Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
13.5.7.3.1. Transfection
13.5.7.3.2. Gene
Therapy
13.5.7.3.3. Recombinant
DNA Technology
13.5.7.3.4. Others
13.5.7.4. Southeast
Asia Plasmid Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type
Plasmid
13.5.8.1.1. Conjugative
13.5.8.1.2. Non-Conjugative
13.5.8.2. Rest
of Asia Pacific Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific
Plasmid Types
13.5.8.2.1. F-Plasmids
13.5.8.2.2. Resistance
Plasmids
13.5.8.2.3. Virulence
Plasmids
13.5.8.2.4. Degradative
Plasmids
13.5.8.2.5. Col
Plasmids
13.5.8.2.6. Cryptic
Plasmids
13.5.8.3. Rest
of Asia Pacific Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
13.5.8.3.1. Transfection
13.5.8.3.2. Gene
Therapy
13.5.8.3.3. Recombinant
DNA Technology
13.5.8.3.4. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
General Type Plasmid
13.6.3. By
Specific Plasmid Types
13.6.4. By
Application
14. Middle East and Africa Plasmid Market Analysis and Forecasts,
2019 - 2027
14.1. Overview
14.1.1. Middle
East and Africa Plasmid Market Revenue (US$ Mn)
14.2. Middle
East and Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type
Plasmid
14.2.1. Conjugative
14.2.2. Non-Conjugative
14.3. Middle
East and Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific
Plasmid Types
14.3.1. F-Plasmids
14.3.2. Resistance
Plasmids
14.3.3. Virulence
Plasmids
14.3.4. Degradative
Plasmids
14.3.5. Col
Plasmids
14.3.6. Cryptic
Plasmids
14.4. Middle East
and Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
14.4.1. Transfection
14.4.2. Gene
Therapy
14.4.3. Recombinant
DNA Technology
14.4.4. Others
14.5. Middle
East and Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
14.5.1.1.1. Conjugative
14.5.1.1.2. Non-Conjugative
14.5.1.2. Saudi
Arabia Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
14.5.1.2.1. F-Plasmids
14.5.1.2.2. Resistance
Plasmids
14.5.1.2.3. Virulence
Plasmids
14.5.1.2.4. Degradative
Plasmids
14.5.1.2.5. Col
Plasmids
14.5.1.2.6. Cryptic
Plasmids
14.5.1.3. Saudi
Arabia Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1.3.1. Transfection
14.5.1.3.2. Gene
Therapy
14.5.1.3.3. Recombinant
DNA Technology
14.5.1.3.4. Others
14.5.2. UAE
14.5.2.1. UAE
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
14.5.2.1.1. Conjugative
14.5.2.1.2. Non-Conjugative
14.5.2.2. UAE
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
14.5.2.2.1. F-Plasmids
14.5.2.2.2. Resistance
Plasmids
14.5.2.2.3. Virulence
Plasmids
14.5.2.2.4. Degradative
Plasmids
14.5.2.2.5. Col
Plasmids
14.5.2.2.6. Cryptic
Plasmids
14.5.2.3. UAE
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
14.5.2.3.1. Transfection
14.5.2.3.2. Gene
Therapy
14.5.2.3.3. Recombinant
DNA Technology
14.5.2.3.4. Others
14.5.3. Egypt
14.5.3.1. Egypt
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
14.5.3.1.1. Conjugative
14.5.3.1.2. Non-Conjugative
14.5.3.2. Egypt
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
14.5.3.2.1. F-Plasmids
14.5.3.2.2. Resistance
Plasmids
14.5.3.2.3. Virulence
Plasmids
14.5.3.2.4. Degradative
Plasmids
14.5.3.2.5. Col
Plasmids
14.5.3.2.6. Cryptic
Plasmids
14.5.3.3. Egypt
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.3.1. Transfection
14.5.3.3.2. Gene
Therapy
14.5.3.3.3. Recombinant
DNA Technology
14.5.3.3.4. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
14.5.4.1.1. Conjugative
14.5.4.1.2. Non-Conjugative
14.5.4.2. Kuwait
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
14.5.4.2.1. F-Plasmids
14.5.4.2.2. Resistance
Plasmids
14.5.4.2.3. Virulence
Plasmids
14.5.4.2.4. Degradative
Plasmids
14.5.4.2.5. Col
Plasmids
14.5.4.2.6. Cryptic
Plasmids
14.5.4.3. Kuwait
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.3.1. Transfection
14.5.4.3.2. Gene
Therapy
14.5.4.3.3. Recombinant
DNA Technology
14.5.4.3.4. Others
14.5.5. South
Africa
14.5.5.1. South
Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
14.5.5.1.1. Conjugative
14.5.5.1.2. Non-Conjugative
14.5.5.2. South
Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
14.5.5.2.1. F-Plasmids
14.5.5.2.2. Resistance
Plasmids
14.5.5.2.3. Virulence
Plasmids
14.5.5.2.4. Degradative
Plasmids
14.5.5.2.5. Col
Plasmids
14.5.5.2.6. Cryptic
Plasmids
14.5.5.3. South
Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
14.5.5.3.1. Transfection
14.5.5.3.2. Gene
Therapy
14.5.5.3.3. Recombinant
DNA Technology
14.5.5.3.4. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By
General Type Plasmid
14.5.6.1.1. Conjugative
14.5.6.1.2. Non-Conjugative
14.5.6.2. Rest
of Middle East & Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By
Specific Plasmid Types
14.5.6.2.1. F-Plasmids
14.5.6.2.2. Resistance
Plasmids
14.5.6.2.3. Virulence
Plasmids
14.5.6.2.4. Degradative
Plasmids
14.5.6.2.5. Col
Plasmids
14.5.6.2.6. Cryptic
Plasmids
14.5.6.3. Rest
of Middle East & Africa Plasmid Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.6.3.1. Transfection
14.5.6.3.2. Gene
Therapy
14.5.6.3.3. Recombinant
DNA Technology
14.5.6.3.4. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
General Type Plasmid
14.6.3. By
Specific Plasmid Types
14.6.4. By
Application
15. Latin America Plasmid Market Analysis and Forecasts, 2019 -
2027
15.1. Overview
15.1.1. Latin
America Plasmid Market Revenue (US$ Mn)
15.2. Latin
America Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
15.2.1. Conjugative
15.2.2. Non-Conjugative
15.3. Latin
America Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid
Types
15.3.1. F-Plasmids
15.3.2. Resistance
Plasmids
15.3.3. Virulence
Plasmids
15.3.4. Degradative
Plasmids
15.3.5. Col
Plasmids
15.3.6. Cryptic
Plasmids
15.4. Latin
America Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
15.4.1. Transfection
15.4.2. Gene
Therapy
15.4.3. Recombinant
DNA Technology
15.4.4. Others
15.5. Latin America
Plasmid Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
15.5.1.1.1. Conjugative
15.5.1.1.2. Non-Conjugative
15.5.1.2. Brazil
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
15.5.1.2.1. F-Plasmids
15.5.1.2.2. Resistance
Plasmids
15.5.1.2.3. Virulence
Plasmids
15.5.1.2.4. Degradative
Plasmids
15.5.1.2.5. Col
Plasmids
15.5.1.2.6. Cryptic
Plasmids
15.5.1.3. Brazil
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.3.1. Transfection
15.5.1.3.2. Gene
Therapy
15.5.1.3.3. Recombinant
DNA Technology
15.5.1.3.4. Others
15.5.2. Argentina
15.5.2.1. Argentina
Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type Plasmid
15.5.2.1.1. Conjugative
15.5.2.1.2. Non-Conjugative
15.5.2.2. Argentina
Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific Plasmid Types
15.5.2.2.1. F-Plasmids
15.5.2.2.2. Resistance
Plasmids
15.5.2.2.3. Virulence
Plasmids
15.5.2.2.4. Degradative
Plasmids
15.5.2.2.5. Col
Plasmids
15.5.2.2.6. Cryptic
Plasmids
15.5.2.3. Argentina
Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
15.5.2.3.1. Transfection
15.5.2.3.2. Gene
Therapy
15.5.2.3.3. Recombinant
DNA Technology
15.5.2.3.4. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Plasmid Market Revenue (US$ Mn) and Forecasts, By General Type
Plasmid
15.5.3.1.1. Conjugative
15.5.3.1.2. Non-Conjugative
15.5.3.2. Rest
of Latin America Plasmid Market Revenue (US$ Mn) and Forecasts, By Specific
Plasmid Types
15.5.3.2.1. F-Plasmids
15.5.3.2.2. Resistance
Plasmids
15.5.3.2.3. Virulence
Plasmids
15.5.3.2.4. Degradative
Plasmids
15.5.3.2.5. Col
Plasmids
15.5.3.2.6. Cryptic
Plasmids
15.5.3.3. Rest
of Latin America Plasmid Market Revenue (US$ Mn) and Forecasts, By Application
15.5.3.3.1. Transfection
15.5.3.3.2. Gene
Therapy
15.5.3.3.3. Recombinant
DNA Technology
15.5.3.3.4. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
General Type Plasmid
15.6.3. By
Specific Plasmid Types
15.6.4. By
Application
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2018
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. Aldevron
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Altogen
Biosystems
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Applied
StemCell
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Cobra
Biologics
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Copernicus
Therapeutics, Inc.
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. GenePharma
Co., Ltd.
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. GenScript
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. InvivoGen
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. MaxCyte,
Inc.
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Miltenyi
Biotec
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT Analysis
17.10.7. Business
Strategies
17.11. Mirus
Bio LLC
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. MolMed
S.p.A.
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. Oxford
Genetics Ltd.
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business
Strategies
17.14. PlasmidFactory
GmbH & Co. KG
17.14.1. Company
Details
17.14.2. Company
Overview
17.14.3. Product
Offerings
17.14.4. Key
Developments
17.14.5. Financial
Analysis
17.14.6. SWOT
Analysis
17.14.7. Business
Strategies
17.15. Polyplus
Transfection
17.15.1. Company
Details
17.15.2. Company
Overview
17.15.3. Product
Offerings
17.15.4. Key
Developments
17.15.5. Financial
Analysis
17.15.6. SWOT
Analysis
17.15.7. Business
Strategies
17.16. Takara
Bio Inc.
17.16.1. Company
Details
17.16.2. Company
Overview
17.16.3. Product
Offerings
17.16.4. Key
Developments
17.16.5. Financial
Analysis
17.16.6. SWOT
Analysis
17.16.7. Business
Strategies
17.17. VGXI,
Inc.
17.17.1. Company
Details
17.17.2. Company
Overview
17.17.3. Product
Offerings
17.17.4. Key
Developments
17.17.5. Financial
Analysis
17.17.6. SWOT
Analysis
17.17.7. Business
Strategies
17.18. Other
Market Participants
Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.